Biomarker for Antibiotic Associated Kidney Damage in Patients With Cystic Fibrosis

Methods for identifying a common side effect in children receiving drug treatments for Cystic fibrosis.

New study highlights effective methods for identifying a common side effect in children receiving drug treatments for Cystic fibrosis. The study conducted by the University of Liverpool is published in Nature Scientific Reports.

The genetic disorder, cystic fibrosis (CF) is characterised by secondary bacterial lung infections, often by a specific resistant bacteria, Pseudomonas aeruginosa. Antibiotics known as aminoglycosides have good efficacy against this bacteria and are often used to treat these infections.

Lung Bacterial Infections Start Early in Children with Cystic Fibrosis
Respiratory bacterial infections can cause structural damage to the lungs and upper airway tissues in children with cystic fibrosis from their early stages of life.

‘KIM-1 may be a useful, non-invasive, biomarker of acute and chronic kidney damage associated with exposure to aminoglycosides in patients with Cystic Fibrosis.’

However, aminoglycosides are potentially damaging to the kidneys. Despite risk reduction strategies, current or recent aminoglycoside exposure is strongly associated with acute kidney injury (AKI) in children with CF.

Biomarkers

Current methods for assessing kidney injury rely on the measurement of serum creatinine, a measure of kidney filtration. Unfortunately this method only highlights injury once significant damage has already occurred. This is particularly dangerous for children.

Cystic Fibrosis Treatment Using an Enzyme That Activates Chloride
Activation of the chloride channel in the lungs could help in the functioning of the lungs in those with cystic fibrosis.

To identify patients at increased risk of kidney damage there is a need for the development of improved biomarkers that not only reflect the site of toxicity, but can identify damage at an earlier stage than currently possible.

To help identify biomarkers, researchers from the Universities of Liverpool and University College London, recruited more than 150 children and young adults up to 20 years of age with a confirmed diagnosis of CF. The participants provided urine samples for measurement of specific proteins, KIM-1 and NGAL, at regular outpatient appointments, and before, during and after exposure to clinically-indicated treatment with anaminoglycoside.

Cystic Fibrosis Treatment Made Effective With Quorum-sensing Inhibitors
By reducing the bacterial production of harmful residues using quorum-sensing inhibitors, drug therapy for cystic fibrosis can be effective.

The researchers found that the concentrations of both KIM-1 and NGAL increased during exposure to an aminoglycoside. These increases occurred in the absence of increases in serum creatinine, and therefore likely represent renal damage without loss of function, commonly termed 'subclinical AKI'. The baseline (before treatment) concentration of KIM-1 increased with cumulative lifetime aminoglycoside exposure, suggesting it may also identify chronic renal damage.

Useful and non-invasive

Health Insurance Aids in Treatment for Cystic Fibrosis
Improved access to medical care under the Medicaid Children's Health Insurance Program has an impact on the recovery from cystic fibrosis.

The study was led by Dr Steve McWilliam a National Institute of Health Research Academic Clinical Lecturer in Paediatric Clinical Pharmacology from the University of Liverpool's Institute of Translational Medicine based at Alder Hey Children's NHS Foundation Trust.

Of the study Dr McWilliam said: "Our research shows that KIM-1 may be a useful, non-invasive, biomarker of acute and chronic kidney damage associated with exposure to aminoglycosides in patients with CF, but its clinical utility needs to be further evaluated in prospective studies."

Source-Eurekalert